Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus

Laura M Stephens; Kathleen A Ross; Kody A Waldstein; Kevin L Legge; Jason S McLellan; Balaji Narasimhan; Steven M Varga

doi:10.4049/jimmunol.2100018

Back

Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus

Journal article

Peer reviewed

Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus

Laura M Stephens, Kathleen A Ross, Kody A Waldstein, Kevin L Legge, Jason S McLellan, Balaji Narasimhan and Steven M Varga

The Journal of immunology (1950), Vol.206(9), pp.2122-2134

05/01/2021

DOI: 10.4049/jimmunol.2100018

PMCID: PMC8062305

PMID: 33827894

View Online

Abstract

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in both young children and in older adults. Despite the morbidity, mortality, and high economic burden caused by RSV worldwide, no licensed vaccine is currently available. We have developed a novel RSV vaccine composed of a prefusion-stabilized variant of the fusion (F) protein (DS-Cav1) and a CpG oligodeoxynucleotide adjuvant encapsulated within polyanhydride nanoparticles, termed RSVNanoVax. A prime-boost intranasal administration of RSVNanoVax in BALB/c mice significantly alleviated weight loss and pulmonary dysfunction in response to an RSV challenge, with protection maintained up to at least 6 mo postvaccination. In addition, vaccinated mice exhibited rapid viral clearance in the lungs as early as 2 d after RSV infection in both inbred and outbred populations. Vaccination induced tissue-resident memory CD4 and CD8 T cells in the lungs, as well as RSV F-directed neutralizing Abs. Based on the robust immune response elicited and the high level of durable protection observed, our prefusion RSV F nanovaccine is a promising new RSV vaccine candidate.

Details

Title: Subtitle: Prefusion F-Based Polyanhydride Nanovaccine Induces Both Humoral and Cell-Mediated Immunity Resulting in Long-Lasting Protection against Respiratory Syncytial Virus
Creators: Laura M Stephens - University of Iowa
Kathleen A Ross - Iowa State University
Kody A Waldstein - University of Iowa
Kevin L Legge - University of Iowa
Jason S McLellan - The University of Texas at Austin
Balaji Narasimhan - Iowa State University
Steven M Varga - University of Iowa
Resource Type: Journal article
Publication Details: The Journal of immunology (1950), Vol.206(9), pp.2122-2134
DOI: 10.4049/jimmunol.2100018
PMID: 33827894
PMCID: PMC8062305
NLM abbreviation: J Immunol
ISSN: 0022-1767
eISSN: 1550-6606
Grant note: T32 AI007485 / NIAID NIH HHS R01 AI124093 / NIAID NIH HHS T32 CA078586 / NCI NIH HHS
Language: English
Date published: 05/01/2021
Academic Unit: Graduate College Admin and Gen; Microbiology and Immunology; Pathology; Otolaryngology
Record Identifier: 9984186550902771

Metrics

16 Record Views

13 Times Cited - Web of Science

See more details